Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Summary
The purpose of this study is to assess the drug-drug interaction (DDI) of repinatrabit with ethinyl estradiol/norethindrone or norethisterone (EE/NE), metformin, rosuvastatin, carbamazepine, and methotrexate in healthy participants.
Official title: A Phase 1, 4-arm, Open-label, Drug-drug Interaction Trial to Evaluate the Pharmacokinetics of Repinatrabit Oral Tablets When Co-administered With Ethinyl Estradiol/Norethindrone, Metformin, Carbamazepine, Rosuvastatin, and Methotrexate in Healthy Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2026-03-20
Completion Date
2026-06-12
Last Updated
2026-03-03
Healthy Volunteers
Yes
Conditions
Interventions
Repinatrabit
Oral tablet.
EE/NE
Oral tablet.
Metformin
Oral tablet.
Rosuvastatin
Oral tablet.
Methotrexate
Oral tablet.
Carbamazepine
Oral tablet.